Biotechnology Market Research Reports & Industry Analysis

... backing the market. According to Azoth Analytics research report, “Global Biomaterials Market (By Type, By Application, By Region, By Country): Opportunities and Forecasts (2016-2021) – (By Value; By Material Type – Polymer ... – Strategy, Financial Performance)”, Global Biomaterials Market is projected to exhibit a CAGR of around 15.73% during 2016 - 2021.' Few of the leading companies operating in Global Biomaterials Market are Royal DSM ...

Antibody Target, Technology & Pipeline Database: 1-Year Subscription Therapeutic monoclonal antibodies have become a clinically and commercially successful class of drugs. Branded therapeutic antibodies on the market reached ... of the Antibody Target, Technology & Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase. Benefits from the Antibody Pipeline Database: Intuitive ...

... Stem Cells Stem Cell Transplants Classification Cancer Stem Cell Therapy Mechanism of Action Global Cancer Stem Cell Market Analysis Global Cancer Stem Cell Clinical Pipeline by Company & Phase Global Cancer Stem Cell Clinical Pipeline: 32 Therapies Global Cancer Stem Cell Market ...

MARKET INSIGHTS Global stem cell market is expected to grow at a CAGR of 23% for the forecasted period of 2015-2020. The market is segmented on the basis of products, technology and application. Stem cell are ...

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update The Competitive Intelligence Report Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update“ provides a competitor evaluation in the field ...

Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors This Competitive Intelligence report titled PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors“ provides a competitor evaluation in the field of protein- and peptide-based agonists of the parathyroid hormone (PTH) receptor ...

... Biosimilars Market Impact of Biosimilars in US Market Impact of Reimbursement Policies on US Biosimilars Market Zarxio: First Approved Biosimilar in US US Biosimilar Clinical Pipeline By Company, Indication & Phase US Biosimilar Clinical Pipeline: 104 Biosimilars Marketed Biosimilars: 1 Biosimilar ...

... on the latest events that have the potential to shape the oncology biosimilars market. Topics covered include opinions about data from Sandoz ... drive down prices to unsustainable levels and cause the biosimilars market in the US to fail? Update Bulletins include expert insight and analysis based on FirstWord ...

... to accept biosimilars of proven targeted treatments. So what do pharma companies need to do to increase confidence and ensure uptake of biosimilars in this toughest of markets? Biosimilars in Oncology: KOL Insight spells out the concerns about equivalence, evidence and endpoints with insights into the current ...

... , Filgrastim/Pegfilgrastim/ Insulin/Lantus apart from other key complex Mab Biosimilar opportunities and list out niche opportunities in biosimilar space in Japan. It details all major consolidation activities ...

... and other factors, China's stem cell therapy develops slowly. At present, China has not approved any stem cell drug product for marketing. As for stem cell research, Chinese ... development and prospects, etc. of global stem cell industry; Policies, upstream/midstream/downstream development, etc. of China stem cell industry; Operation, stem cell business, etc. of 8 upstream companies ...

... European biosimilars market. “Europe Biosimilars Market Opportunity Outlook 2020” Report Highlight: Europe Biosimilars Market Outlook Europe Biosimilars Market Trend Analysis by Country Introduction of Biosimilars in European Market by Segment Clinical & Non Clinical Guidelines Europe Biosimilar ...

... significant regulatory progress has been made in recent years, clarity is distinctly lacking on certain issues, such as interchangeability and naming.  FirstWord’s Biosimilars: Regulatory Outlook provides insight and opinion on why. This 64 page report gives in-depth and candid views on what eight industry and biosimilar experts ...

... research report, “Opportunities in Indian Stem Cell Market”, India has the potential to become one of the fastest growing stem cell markets in the world, mainly owing to Stem Cell Banking segment ... authored to evaluate the Indian Stem Cell Market in terms of Stem Cell Banking and Stem Cell Research, so as to identify the market potential and future growth opportunities. It provides extensive research ...

... of Chinese stem cells medicine industry; To analyze major rivals of stem cells medicine in China; To disclose market size of China’s stem cells medicine industry; To discuss influence of governmental regulation on stem cells medicine ... demands of stem cells medicine; To understand position of China’s stem cells medicine in the world; To predict what future of China’s stem cells medicine industry will be; To reveal opportunities in Chinese stem cells medicine ...

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis The Competitive Intelligence report Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis describes product ... G-CSF products represent an attractive market size for biosimilar proteins in regulated markets. Biosimilar filgrastim products have already been introduced into the the ...

... Stem Cell Therapies Clinical Pipeline by Company, Indication & Phase Global Stem Cell Therapies in Clinical Pipeline: 114 Therapies Majority Stem Cell Therapies in Preclinical Phase: 38 Therapies Marketed Stem Cell Therapies Clinical Insight by Brand Name, Company & Indication Marketed Stem Cell Therapies ...

... market will at some point provide a secondary benchmark for biosimilar developers, physicians, patients and payers, when data from a much anticipated 500-patient switching study ... in the EU5 the following questions this week… Has your view towards current/future usage of biosimilar TNF inhibitors become more ...

... and effectiveness of medical implants and its associated procedures. This has contributed considerably to the growth of the biomaterials market. The global implantable biomaterials market is segmented on materials types, applications and region. Depending on the materials type the market is segmented into four ...

... physician sentiment to the CMS guidance. In our first poll, focused on Part B reimbursement, we are asking oncologists… How effective they expect the CMS reimbursement guidance to be in incentivising physicians ... of 'de-facto' interchangeability via CMS guidance Their view on interchangeability status for ...

Competitor Analysis: The rapeutic Antibodies 2015: Biosimilars & Biosuperiors This Competitive Intelligence Report about The rapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor ...

... Global Nanomedicine Market & Pipeline Insight 2015” Report Highlights: Global Nanomedicine Market Outlook Global Nanomedicine Market Dynamics Global Nanomedicine Clinical Pipeline by Company, Indication & Phase Global Nanomedicine Clinical Pipeline: 144 Nanomedicines Marketed Nanomedicines: 13 Nanomedicines ...

Competitor Analysis: EGF-R Antibodies 2015 – Biosuperiors and Biosimilars of Erbitux This Competitive Intelligence Report about EGF-R Antibodies 2015 – Biosuperiors and Biosimilars of Erbitux provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2015 ...

Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab This Competitive Intelligence Report about CD20 Antibodies 2015- Biosimilars and Biosuperiors of Rituximab provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated ...

Competitor Analysis: TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel The present Competitive Intelligence report about TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel provides a competitor evaluation in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha ...

... for. FirstWord polled US-based oncologists on this issue, among others, following the ODAC meeting in January (see Physician Views Poll Results: Positive FDA sentiment for biosimilar Neupogen shared by oncologists). While Zarxio is a trailblazer in the ...

Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin This Competitive Intelligence Report about Her2 Antibodies 2015 - Biosimilars and ... and make out about 81% of the franchise sale. Therefore, the Her2 antibody market is not only highly attractive for biosimilar developments ...

Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis This Competitive Intelligence Report about VEGF and VEGF-R ... more cancer and eye disease indications. The commercial success of the VEGF antibodies and the expiry of patent protection has laid the ground ...

... , Spain and Italy, Medical Affairs Reputations (EU5): Biosimilar mAbs in Inflammatory Disorders offers insights on how Medical Affairs teams from companies developing and marketing biosimilar anti-TNF monoclonal ... , Spain, the UK; EU5 – biosimilar mAb developers and companies marketing branded mAbs require solid evidence upon which to base medical affairs’ strategy for their ...

... players (Daiichi-Sankyo, KHK), JP Innovator+ GE companies (Meiji, Fujifilm, Nippon Kayaku, Mochida, and Kissei), Global Multinationals (Pfizer, Sandoz) and some rising star JP local companies (Yoshindo, Gene Techno Science, Sanwa Kagaku ...

... with aging (dementia, Alzheimer's etc.) are on the rise!. Consequently the pharma industry continues to grow and is projected ... the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic have reached a critical mass warranting a ...

... “Global Biosimilar Market: Trends & Opportunities (2015 Edition)” analyzes the global biologics market, with exhaustive discussion on demand of Biosimilars with increase in patent expiry of innovator drugs. The key market ... titled “The Global Biosimilar Market: Trends & Opportunities (2014-2018)” provides an in-depth analysis of the growing Biosimilar Market with detailed analysis of market sizing and growth, market share and ...

... bio-based materials and to make short-term prediction. The above hot topics in China’s bio-based materials market will be explored and reported by CCM in detail in this e-journal, Bio-based Materials China News 1412 ...

... have historically had minimal opportunity to leverage discounts from an oligopolistic ... well established players, it remains to be seen how comfortable physicians would be using a 'biosimilar' insulin developed by ... as 'interchangeable' with branded Lantus). Similarly, what percentage of patients would you be ...

... Lucentis, while the availability of compounded Avastin, used as an alternative to Lucentis at a much cheaper cost, adds further confusion to the market outlook. Furthermore, a Physician Views ... therapies persists). FirstWord's Biosimilar Index reveals just one biosimilar Lucentis product in development; PF582 ...

... Europe Biosimilars Market & Pipeline Insight” Report Highlight: Biosimilars Market Overview & Trend Analysis by Country Biosimilars Introduction Timeline in Europe Biosimilars Development & Market Authorization Guidelines Biosimilars Clinical Pipeline by Phase, Indication, Company & Country Marketed ...

... biosimilars products being developed owing to a significant number of leading brands of biologic drugs losing their patents by 2020. “Global Biosimilars Market Regulations & Pipeline Insight” Report Highlights: Market Overview Detailed Regulatory Pathways For 12 Countries/Regions Global Biosimilars Pipeline by Phase, Indication, Company & Country Biosimilars Pipeline ...

... , the FDA published new guidance on the requirements for developing biosimilars for the US market – specifically focused on clinical pharmacology requirements ... , but potentially how they are used by physicians. In light of the FDA's new guidance, FirstWord is polling US-based oncologists and rheumatologists ...

... , to legal challenges and questions about its profitability, The Future of Biosimilars: Mapping Critical Uncertainties and the Impact of Future Events provides ... and most up-to-date access to recent and future events in the biosimilars market, including battles being waged over policy, regulatory, intellectual ...

... of the bio-based chemical fiber industry and its raw materials in China. 2. In recent years, conventional plasticizers have received ... biomass PVA industry and will further devote itself to its development. 8. A new production process developed will effectively lower the production costs of succinic acid ...

... are physicians ready for biosimilars and is the industry doing enough to educate who is arguably the key stakeholder in this market? As physician ... for biosimilar developers and Physician Views: At least some similarity needed in biosimilar naming conventions, say majority of physicians, but caveats remain In a ...

... is not, significant. That is where the Biosimilar Index comes in. A new force in biosimilar and NCB drug and market tracking FirstView’s Biosimilar Index is a new, comprehensive drug intelligence ... both on-going tracking of development and interpretation of the commercial and clinical significance. Two class beating services in one subscription! Biosimilar Index: Pipeline Database ...

... and allow online work with the project data to print or export an individual report. With the approval and launch of next generation Her2 ... cancer. In addition, the report lists company-specific R&D pipelines of Her2 antibodies. Competitor projects are listed in a tabular format providing information on: Drug ...

... what do physicians think? What do they consider to be the correct naming convention and how will this impact their potential usage of biosimilars. This week's Physician Views poll will ask US and EU5-based oncologists and rheumatologists: What naming convention for biosimilar products they believe ...

... in India. Till date around six major private players, both Indian as well subsidiaries of international companies are operating in the stem cell banking market of India. “India Cord Blood Stem Cell Banking Market” research report outlines following aspects related to booming stem cell banking in India: India Stem Cell Research & Therapy Market Overview Cord Blood Stem Cell Banking ...

... governments and private players worldwide stepping into this industry, the market shows bright prospects and immense opportunities to cash in on. As per the estimations of our latest report, “Global EPO Biosimilars Market Outlook 2018”, the global EPO biosimilars market will grow at a CAGR of around 37% ...

... to drive a notable shift in the Indian trastuzumab market, this week's Physician Views poll asks Indian oncologists to provide their initial views on what its availability will ... drug) or across the HER2-positive breast cancer treatment paradigm? How confident they are in using CANMAb given the relative size ...

Umbilical cord blood stem cells are potential stem cells that can convert into any type of -determined cells. Global stem cell market ... transplant Transplant Medicine Regenerative Medicine Others Cord Blood Banking Blood Transfusion Cell Based Genetics Global Stem cell UCB market by Geography UCB market ...

... of the global market for biosimilars by 2020. “South Korea Biosimilar Market Analysis” reports gives comprehensive details on following aspects related to Biosimilar development in South Korea: Market Overview Favorable Market Parameters Biosimilar Pipeline Analysis by Company, Phase ...

... world in biosimilar sales. Although the European experience differs markedly from the anticipated evolution of biosimilars in the US, there are lessons to be learned. In Commercialisation of Biosimilars: strategies for ... of how to design strategies to influence key opinion leaders Understand why biosimilar acceptance is slower than most new generic drugs Commercialisation of Biosimilars: strategies for market penetration ...